Genentech panel advises against Roche's takeover bid

02/23/2009 | Financial Times (free content) · San Francisco Chronicle

A three-member committee of Genentech directors unanimously recommended that shareholders reject Roche's $42 billion buyout bid, saying the offer "substantially undervalues" the biotech company. "We are disappointed that Roche has chosen not to consider an appropriate price range for Genentech's minority shares or to constructively negotiate with our committee, and we must recommend that stockholders not tender their shares as a result," they wrote in a statement.

View Full Article in:

Financial Times (free content) · San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY